TSE:BU

Burcon NutraScience Competitors

C$5.42
+0.05 (+0.93 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$5.36
Now: C$5.42
C$5.65
50-Day Range
C$3.90
MA: C$4.66
C$5.37
52-Week Range
C$0.91
Now: C$5.42
C$5.92
Volume303,519 shs
Average Volume576,574 shs
Market CapitalizationC$580.49 million
P/E Ratio5,420.00
Dividend YieldN/A
BetaN/A

Competitors

Burcon NutraScience (TSE:BU) Vs. TRIL, CXR, APS, TH, BLU, and NRI

Should you be buying BU stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Burcon NutraScience, including Trillium Therapeutics (TRIL), Concordia International (CXR), Aptose Biosciences (APS), Theratechnologies (TH), BELLUS Health (BLU), and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).

Burcon NutraScience (TSE:BU) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Burcon NutraScience and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Trillium Therapeutics0000N/A

Burcon NutraScience currently has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Trillium Therapeutics has a consensus target price of C$25.00, indicating a potential upside of 91.42%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Burcon NutraScience.

Profitability

This table compares Burcon NutraScience and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
Trillium TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Burcon NutraScience and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00
Trillium TherapeuticsC$148,000.008,886.89C$-88,724,629.00C($0.88)-14.82

Burcon NutraScience has higher earnings, but lower revenue than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Concordia International and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Valuation & Earnings

This table compares Concordia International and Burcon NutraScience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Concordia International has higher revenue and earnings than Burcon NutraScience. Concordia International is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Concordia International and Burcon NutraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
Burcon NutraScience00103.00

Burcon NutraScience has a consensus price target of C$5.00, indicating a potential downside of 7.75%.

Summary

Concordia International beats Burcon NutraScience on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Burcon NutraScience and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Valuation & Earnings

This table compares Burcon NutraScience and Aptose Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79

Burcon NutraScience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Burcon NutraScience and Aptose Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Aptose Biosciences00203.00

Burcon NutraScience presently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Burcon NutraScience and Theratechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Theratechnologies02002.00

Burcon NutraScience presently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Theratechnologies has a consensus price target of C$3.75, suggesting a potential downside of 21.38%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, equities analysts clearly believe Burcon NutraScience is more favorable than Theratechnologies.

Valuation & Earnings

This table compares Burcon NutraScience and Theratechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00
TheratechnologiesC$66.05 million6.78C$-27,589,254.00C($0.29)-16.22

Burcon NutraScience has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Burcon NutraScience and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
TheratechnologiesN/AN/AN/A

Summary

Burcon NutraScience beats Theratechnologies on 7 of the 8 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BELLUS Health and Burcon NutraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Burcon NutraScience00103.00

Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, analysts plainly believe Burcon NutraScience is more favorable than BELLUS Health.

Earnings and Valuation

This table compares BELLUS Health and Burcon NutraScience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$15,000.0028,462.44C$-42,145,306.00C($0.54)-10.13
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Burcon NutraScience has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats BELLUS Health on 6 of the 8 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.38C$-6,980,844.00C($0.61)-58.64
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Burcon NutraScience has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Burcon NutraScience00103.00

Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Given Burcon NutraScience's higher possible upside, analysts clearly believe Burcon NutraScience is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 5 of the 6 factors compared between the two stocks.


Burcon NutraScience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics
0.9$13.06+7.6%C$1.32 billionC$148,000.00-14.82News Coverage
Gap Down
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.61+1.7%C$587.53 millionN/A-9.79
Theratechnologies logo
TH
Theratechnologies
0.7$4.77+0.8%C$447.62 millionC$66.05 million-16.22Upcoming Earnings
News Coverage
BLU
BELLUS Health
0.5$5.45+1.5%C$426.94 millionC$15,000.00-10.13Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.95+0.6%C$409.34 millionC$76.09 million-58.64News Coverage
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.77+4.0%C$292.92 millionC$52.78 million-1.31Gap Up
MDNA
Medicenna Therapeutics
0.5$5.08+0.8%C$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99+16.2%C$259.90 millionN/A-8.91News Coverage
Gap Down
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62+0.6%C$245.11 millionC$3,000.00-6.26
ATE
Antibe Therapeutics
1.3$4.88+1.0%C$222.07 millionC$9.33 million-6.20Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.82+6.5%C$203.34 millionC$170,000.00-10.24
RVX
Resverlogix
0.7$0.86+0.0%C$202.07 millionN/A78.18Upcoming Earnings
HBP
Helix BioPharma
0.5$0.92+1.1%C$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41+4.9%C$123.03 millionC$17.18 million-72.01News Coverage
Gap Up
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.68+1.5%C$88.79 millionC$81,000.0025.19Gap Down
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
PMN
ProMIS Neurosciences
0.5$0.22+0.0%C$67.31 millionC$1,787.00-11.00
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.55+3.6%C$60.20 millionC$11.64 million-10.78News Coverage
Gap Up
SBM
Sirona Biochem
0.5$0.38+1.3%C$58.80 millionC$123,870.00-29.23
COV
Covalon Technologies
0.6$1.41+9.2%C$37.44 millionC$23.84 million-5.92News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.29+1.7%C$34.02 millionC$13.02 million-0.42
IGX
IntelGenx Technologies
0.9$0.57+3.5%C$30.87 millionC$1.54 million-8.77News Coverage
QPT
Quest PharmaTech
0.8$0.11+9.1%C$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72+4.2%C$21.65 millionC$16.14 million21.82News Coverage
CTX
Crescita Therapeutics
0.6$0.86+2.3%C$17.76 millionC$15.64 million430.00
KNE
Kane Biotech
0.4$0.17+0.0%C$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27+3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09+5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60+5.0%C$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39+3.8%C$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49+1.0%C$9.07 millionN/A-2.92News Coverage
Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36+1.4%C$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15+13.3%C$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$6.40+15.3%C$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.